NasdaqGS:NVCRMedical Equipment
NovoCure (NVCR) Gains Japan Approval For Optune Lua® In NSCLC Treatment Combo
NovoCure (NVCR) recently secured approval for its Optune Lua® device in Japan, a milestone for the company’s TTFields therapy that targets non-small cell lung cancer. This development aligns with the company’s strategic efforts to broaden its therapy applications. Over the past month, NovoCure's stock rose 3.58%. This movement was largely in line with market trends, as broader stock indexes experienced gains ahead of anticipated interest rate cuts by the Federal Reserve. The approval of...